Jun Tan , Ph.D, M.D.

Robert A. Silver Chair in Developmental Neurobiology
Professor
Director of Developmental Neurobiology Laboratory
Silver Child Development Center

Education

  • Post-Doc., Immunology Program, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida College of Medicine, Tampa, Florida, 1996-1998
  • Post-Doc., Department of Medical Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA, 1990-1992
  • Ph.D., Immunology, Third Military Medical University, Chongqing, China - 1987-1989 M.S., Human Genetics, Institute of Genetics of Fudan University, Shanghai, China, 1987-1989
  • M.D. training (B.Ms.), Medicine, Third Military Medical University, Chongqing, China, 1978-1983

Bio-sketch

Honors and Awards

  • Robert A. Silver Chair in Developmental Neurobiology (2007)
  • Investigator-Initiated Award: Alzheimer Association (2003)
  • Young Investigator Research Award, National Science Foundation of China, 1992
    Achievement Award for Science and Technology in China, 1994
  • National Outstanding Oversea Young Scientist Award, National Science Foundation of China, 2002
  • 2002 Principal Investigator-Alzheimer Association-IIRG-02-4064-Role of CD40L in Gliosis and Amyloidosis in Alzheimer Transgenic Mice

Grants

  • IMPLICATION OF HUCBC: A NOVEL THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE ($284,928.00, 08/01/2009-07/31/2014)
  • IMPLICATION OF HUCBC: A NOVEL THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE ($296,429.00, 08/01/2009-07/31/2014)
  • IMPLICATION OF HUCBC: A NOVEL THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE ($299,423.00, 08/01/2009-07/31/2014)
  • IL-6-MEDIATED JAK2-STAT3 SIGNALING AND BRAIN DEVELOPMENT ($181,913.00, 09/01/2010-06/30/2013)
  • HUCBC MODULATION OF ALZHEIMER'S-LIKE PATHOLOGY AND BEHAVIORAL CHANGES ($118,970.00, 09/15/2010-02/28/2013)
  • HUCBC MODULATION OF ALZHEIMER'S-LIKE PATHOLOGY AND BEHAVIORAL CHANGES ($44,183.00, 09/15/2010-02/28/2013)
  • HUCBC MODULATION OF ALZHEIMER'S-LIKE PATHOLOGY AND BEHAVIORAL CHANGES ($314,402.00, 09/15/2010-02/28/2013)
  • STATIN MODULATION OF IMMUNOTHERAPY FOR ALZHEIMER DISEASE ($34,821.00, 08/25/2011-08/24/2012)

Select Publications

  • Antoinette B, Giunta B, Obregon D, Nikolic W, Tian J, Sanberg C, Sutton D and Tan J.
    Peripheral biomarkers in Autism: sAPP-α as a probable key player in early diagnosis.
    Int J Clin Exp Med 1(4):338-44 (2008).
  • Town T, Laouar Y, Pittenger C, Mori T, Szekely C, Tan J, Duman R and Flavell R.
    Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer's-like pathology.
    Nat Med 14(6):681-7 (2008).
  • Zhu YY, Hou HY, Nikolic W, Bickford P, Giunta B and Tan J.
    CD45RB is a novel molecular therapeutic target to inhibit Aβ peptide-induced microglial MAPK activation.
    PLoS ONE 3(5):e2135 (2008).
  • Nikolic WV, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle D, Giunta B, Morgan D, Town T and Tan J.
    Transcutaneous β-amyloid immunization of transgenic Alzheimer's mice reduces cerebral β-amyloid deposits without T-cell infiltration and microhemorrhage.
    Proc Natl Acad Sci USA 104:2507-2512 (2007).
  • Obregon D, Rezai-Zadeh K, Zeng J, Shytle D, Town T and Tan J.
    ADAM10 activation is required for green tea EGCG-induced α-secretase cleavage of amyloid precursor protein.
    J Biol Chem 281 (24):16419-16427 (2006).